Form 8-K BridgeBio Pharma, Inc. For: Jan 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BridgeBio issues $632.5 million convertible notes due 2033
January 21, 2026 4:14 PM ESTBridgeBio Pharma Inc. (NASDAQ: BBIO) issued $632.5 million in convertible senior notes due 2033 through a private offering to qualified institutional buyers on January 21, 2026, according to a company statement.
The notes carry a 0.75% annual interest rate and mature on February 1, 2033. Interest payments occur semiannually on February 1 and August 1, beginning August 1, 2026.... More
